In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

EasyJet was a big FTSE 100 faller, down 3.1 per cent, or 17p, to 540.4p and British Airways owner IAG - a top blue-chip ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...